Skip to main content
. 2017 Nov 18;6(11):e006901. doi: 10.1161/JAHA.117.006901

Figure 2.

Figure 2

Efficacy outcomes by sex. Women had a significant 22% reduction of myocardial infarction and a 12% reduction of major adverse cardiac events (composite of cardiovascular death, myocardial infarction, and stroke) with ezetimibe compared with placebo. There were no significant treatment interactions by sex for any of the end points. CHD indicates coronary heart disease; CI, confidence interval; Eze, ezetimibe; HR, hazard ratio; KM, Kaplan‐Meier; PBO, placebo; P int, P value for interaction; Simva, simvastatin.